Genome Editing Market Comprehensive Statistics, Growth Rate, and Future Trends 2035

The current technology landscape features over 130 genome editing technologies that have been developed by more than 110 gene editing companies engaged in this domain. Most of these technologies are based on CRISPR technique (84%). It is worth highlighting that, amongst the genome editing technologies, majority (80%) can be employed in in-vivo method for gene delivery. It is also worth mentioning that there are only two technologies developed by gene editing companies are based on zinc finger nucleases technique; these include (in alphabetical order) Nucleofector™ technology (developed by Lonza) and Sangamo’s proprietary zinc finger (ZF) platform.
The global genome editing market size is estimated to grow from USD 3.90 billion in 2024 to USD 14.5 billion by 2035, representing a CAGR of 12.6% during the forecast period till 2035.

Most of the gene editing companies (46) engaged in this domain were established between 2016-2020. Examples of gene editing companies that have been established between 2006-2010 include (in alphabetical order) Applied StemCell, Biocytogen, Feldan Therapeutics, Precision BioSciences, Recombinetics and TransViragen.

Majority (68%) of the genome editing technologies developed by gene editing companies use cells as the delivery, followed by viral vectors (42%). Further, 80% of the technologies developed by gene editing companies can be utilized for drug discovery. Notable examples of genome editing technologies developed by base editing companies include (in alphabetical order, used for diagnostic purpose) DETECTR BOOST (developed by Mammoth Bioscience), ex vivo and in vivo CRISPR/Cas9 genome editing platforms (developed by Intellia Therapeutics), and Pin-point™ base editing platform (developed by Horizon Discovery).
In pursuit of gaining a competitive edge, industry stakeholders are actively innovating and developing novel genome editing technologies that can be utilized across multiple application areas.

The primary purpose of this analysis was to develop a better understanding of the overall potential and capabilities of different technologies available for genome editing. It is worth highlighting that the input data used for this analysis was collated from publicly available sources. Further, at no point should the inferences presented in this section be construed as a recommendation that one technology is better than another.

The following approach was adopted to compare the genome editing technologies available:
• As a starting point, we collated information on the aforementioned parameters for technologies that are being used in genome editing, and thus, were considered for this analysis.
• The gene editing companies were divided into three peer groups based on their location of headquarters (region-wise), including North America, Europe, and Asia-Pacific, Middle East and North Africa and Latin America.

Further, technology competitiveness was assessed score for gene editing companies using developer power (in terms of years of experience of the developer), technology strength (in terms of type of gene editing technique, gene editing approach, in-silico analysis, type of gene delivery method, type of gene delivery modality, highest phase of drug development supported and application area).
Close to 1,000 patents related to genome editing have been filed / granted by the gene editing companies in order to protect the intellectual property generated within this field.
Over the past decade, industry stakeholders have been extensively working towards the development of genome editing technologies. Recently, the domain has witnessed significant advancements, both in terms of introduction of novel technologies to edit the genome and improvisation in the delivery mechanism of the genome editing tools. As a result, a number of patents have been filed / granted to protect the new intellectual capital generated by the gene editing companies engaged in the development of genome editing tools.
During our research, it was observed that majority of the patents filed by gene editing companies (technology developers) in this domain are patent applications (86%), followed by those which have been granted approval (12%). Further, majority of the patents (33%) were filed / granted in North America, followed by Asia-Pacific (27%). Moreover, despite the large number of patents that have been filed by gene editing companies recently (and hence having a long remaining patent life), only 1% of the total patents have the highest relative valuation.

Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.

To view more details on this report, click on the link
https://www.rootsanalysis.com/....reports/genome-editi

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.

Contact Details
Roots Analysis
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/